Moens A, van der Woude CJ, Julsgaard M, et al. - Given that biologicals are often provided to women with inflammatory bowel diseases (IBD) during pregnancy to maintain disease remission, researchers sought to determine pregnancy and child outcomes of vedolizumab-exposed (VDZE) pregnancies. Further, they compared these results with anti-TNF exposed (TNFE) or both immunomodulatory and biologic unexposed (CON IBD) pregnancies. They conducted a multicentre case-control observational study including 79 pregnancies in 73 IBD women in the VDZE group and 186 pregnancies (162 live births) in 164 IBD women and 184 pregnancies (163 live births) in 155 IBD women, in the TNFE and CON IBD group, respectively. This work was identified to be the largest to date to summarize on pregnancy outcomes in IBD patients treated with VDZ. All three groups exhibited a low risk of adverse pregnancy outcomes. After excluding patients with reported active disease at any point in pregnancy, all groups were similar regarding the number of miscarriages. Further, there was no correlation between VDZ use and an increased risk of major congenital anomalies in the offspring. During conception and pregnancy, VDZ use appears to convey a low risk, however, they suggest confirming this in large, prospective trials.